Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity

Angela M. Finch, Shawn M. Vogen, Simon Sherman, Leonid Kirnarsky, Stephen M. Taylor, Sam D. Sanderson

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

A conformationally biased decapeptide agonist of human C5a (C5a65- 74 Y65,F67,P69,P71,D-Ala73 or YSFKPMPLaR) was used as a functional probe of the C5a receptor (C5aR) in order to understand the conformational features in the C-terminal effector region of C5a that are important for C5aR binding and signal transduction. YSFKPMPLaR was a potent, full agonist of C5a, but at higher concentrations had a superefficacious effect compared to the natural factor. The maximal efficacy of this analogue was 216 ± 56% that of C5a in stimulating the release of β-glucuronidase from human neutrophils. C5aR activation and binding curves both occurred in the same concentration range with YSFKPMPLaR, characteristics not observed with natural C5a or more conformationally flexible C-terminal agonists. YSFKPMPLaR was then used as a C-terminal effector template onto which was synthesized various C5aR binding determinants from the N-terminal core domain of the natural factor. In general, the presence of N-terminal binding determinants had little effect on either potency or binding affinity when the C-terminal effector region was presented to the C5aR in this biologically active conformation. However, one peptide, C5a12-20-Ahx-YSFKPMPLaR, expressed a 100-fold increase in affinity for the neutrophil C5aR and a 6-fold increase in potency relative to YSFKPMPLaR. These analyses showed that the peptides used in this study have up to 25% of the potency of C5a in human fetal artery and up to 5% of the activity of C5a in the PMN enzyme release assay.

Original languageEnglish (US)
Pages (from-to)877-884
Number of pages8
JournalJournal of Medicinal Chemistry
Volume40
Issue number6
DOIs
StatePublished - Mar 14 1997

Fingerprint

Anaphylatoxin C5a Receptor
Neutrophils
Signal transduction
Peptides
Glucuronidase
Enzyme Assays
Conformations
complement C5a, (65-74), Tyr(65)-Phe(67)-Pro(69,71)-Ala(73)-
Assays
Signal Transduction
Arteries
Chemical activation
Enzymes

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity. / Finch, Angela M.; Vogen, Shawn M.; Sherman, Simon; Kirnarsky, Leonid; Taylor, Stephen M.; Sanderson, Sam D.

In: Journal of Medicinal Chemistry, Vol. 40, No. 6, 14.03.1997, p. 877-884.

Research output: Contribution to journalArticle

Finch, Angela M. ; Vogen, Shawn M. ; Sherman, Simon ; Kirnarsky, Leonid ; Taylor, Stephen M. ; Sanderson, Sam D. / Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity. In: Journal of Medicinal Chemistry. 1997 ; Vol. 40, No. 6. pp. 877-884.
@article{8761b556af584103917e747f5c427027,
title = "Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity",
abstract = "A conformationally biased decapeptide agonist of human C5a (C5a65- 74 Y65,F67,P69,P71,D-Ala73 or YSFKPMPLaR) was used as a functional probe of the C5a receptor (C5aR) in order to understand the conformational features in the C-terminal effector region of C5a that are important for C5aR binding and signal transduction. YSFKPMPLaR was a potent, full agonist of C5a, but at higher concentrations had a superefficacious effect compared to the natural factor. The maximal efficacy of this analogue was 216 ± 56{\%} that of C5a in stimulating the release of β-glucuronidase from human neutrophils. C5aR activation and binding curves both occurred in the same concentration range with YSFKPMPLaR, characteristics not observed with natural C5a or more conformationally flexible C-terminal agonists. YSFKPMPLaR was then used as a C-terminal effector template onto which was synthesized various C5aR binding determinants from the N-terminal core domain of the natural factor. In general, the presence of N-terminal binding determinants had little effect on either potency or binding affinity when the C-terminal effector region was presented to the C5aR in this biologically active conformation. However, one peptide, C5a12-20-Ahx-YSFKPMPLaR, expressed a 100-fold increase in affinity for the neutrophil C5aR and a 6-fold increase in potency relative to YSFKPMPLaR. These analyses showed that the peptides used in this study have up to 25{\%} of the potency of C5a in human fetal artery and up to 5{\%} of the activity of C5a in the PMN enzyme release assay.",
author = "Finch, {Angela M.} and Vogen, {Shawn M.} and Simon Sherman and Leonid Kirnarsky and Taylor, {Stephen M.} and Sanderson, {Sam D.}",
year = "1997",
month = "3",
day = "14",
doi = "10.1021/jm960727r",
language = "English (US)",
volume = "40",
pages = "877--884",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity

AU - Finch, Angela M.

AU - Vogen, Shawn M.

AU - Sherman, Simon

AU - Kirnarsky, Leonid

AU - Taylor, Stephen M.

AU - Sanderson, Sam D.

PY - 1997/3/14

Y1 - 1997/3/14

N2 - A conformationally biased decapeptide agonist of human C5a (C5a65- 74 Y65,F67,P69,P71,D-Ala73 or YSFKPMPLaR) was used as a functional probe of the C5a receptor (C5aR) in order to understand the conformational features in the C-terminal effector region of C5a that are important for C5aR binding and signal transduction. YSFKPMPLaR was a potent, full agonist of C5a, but at higher concentrations had a superefficacious effect compared to the natural factor. The maximal efficacy of this analogue was 216 ± 56% that of C5a in stimulating the release of β-glucuronidase from human neutrophils. C5aR activation and binding curves both occurred in the same concentration range with YSFKPMPLaR, characteristics not observed with natural C5a or more conformationally flexible C-terminal agonists. YSFKPMPLaR was then used as a C-terminal effector template onto which was synthesized various C5aR binding determinants from the N-terminal core domain of the natural factor. In general, the presence of N-terminal binding determinants had little effect on either potency or binding affinity when the C-terminal effector region was presented to the C5aR in this biologically active conformation. However, one peptide, C5a12-20-Ahx-YSFKPMPLaR, expressed a 100-fold increase in affinity for the neutrophil C5aR and a 6-fold increase in potency relative to YSFKPMPLaR. These analyses showed that the peptides used in this study have up to 25% of the potency of C5a in human fetal artery and up to 5% of the activity of C5a in the PMN enzyme release assay.

AB - A conformationally biased decapeptide agonist of human C5a (C5a65- 74 Y65,F67,P69,P71,D-Ala73 or YSFKPMPLaR) was used as a functional probe of the C5a receptor (C5aR) in order to understand the conformational features in the C-terminal effector region of C5a that are important for C5aR binding and signal transduction. YSFKPMPLaR was a potent, full agonist of C5a, but at higher concentrations had a superefficacious effect compared to the natural factor. The maximal efficacy of this analogue was 216 ± 56% that of C5a in stimulating the release of β-glucuronidase from human neutrophils. C5aR activation and binding curves both occurred in the same concentration range with YSFKPMPLaR, characteristics not observed with natural C5a or more conformationally flexible C-terminal agonists. YSFKPMPLaR was then used as a C-terminal effector template onto which was synthesized various C5aR binding determinants from the N-terminal core domain of the natural factor. In general, the presence of N-terminal binding determinants had little effect on either potency or binding affinity when the C-terminal effector region was presented to the C5aR in this biologically active conformation. However, one peptide, C5a12-20-Ahx-YSFKPMPLaR, expressed a 100-fold increase in affinity for the neutrophil C5aR and a 6-fold increase in potency relative to YSFKPMPLaR. These analyses showed that the peptides used in this study have up to 25% of the potency of C5a in human fetal artery and up to 5% of the activity of C5a in the PMN enzyme release assay.

UR - http://www.scopus.com/inward/record.url?scp=0030946317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030946317&partnerID=8YFLogxK

U2 - 10.1021/jm960727r

DO - 10.1021/jm960727r

M3 - Article

C2 - 9083476

AN - SCOPUS:0030946317

VL - 40

SP - 877

EP - 884

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 6

ER -